Cancer Drug Parity Act of 2019

S 741 Cancer Drug Parity Act of 2019

US Congress 116th Congress

Cancer Drug Parity Act of 2019
S.741


About S.741

Requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are

  • (1) approved by the Food and Drug Administration;
  • (2) medically necessary for the cancer treatment; and
  • (3) clinically appropriate in terms of type, frequency, extent site, and duration.To comply with this requirement, health plans may not, with respect to anticancer medications
  • (1) change or replace benefits to increase out-of-pocket costs,
  • (2) reclassify benefits to increase costs, or
  • (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

  

Bill Texts

Introduced 03/27/2019

Weigh In

No votes yet!
Cast yours now to be the first.

Votes for: 0 Votes against: 0

Sponsors (20)

Sponsors by party

     

Bill Sponsors

History

Read Twice And Referred To The Committee On Health, Education, Labor, And Pensions.

03/12/2019